{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T10:07:24Z","timestamp":1788516444021,"version":"build-2803163510"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T00:00:00Z","timestamp":1525219200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The 13-valent pneumococcal conjugate vaccine (PCV13) and the 23-valent pneumococcal polysaccharide vaccine (PPSV23) were both recommended to adults aged \u226565 years. The study examines adults \u226565 years for risk of adverse events (AEs) requiring medical attention following vaccination with PCV13 as compared with vaccination with PPSV23, a long-standing vaccine with a satisfactory safety profile.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The cohort study included 6 Vaccine Safety Datalink sites. The exposed person-time included follow-up time of the first PCV13 received by subjects age \u226565 years from January 1 to August 15, 2015. The comparator person-time included follow-up time after the first PPSV23 received by subjects of the same age during Janaury 1 to August 15 of each year of 2011\u20132015. The prespecified AEs included cardiovascular events, Bell\u2019s palsy, Guillain-Barr\u00e9 syndrome, syncope, erythema multiforme, thrombocytopenia, cellulitis and infection, allergic reaction, and anaphylaxis. Inverse probability of treatment weighting\u2013adjusted Poisson regression models was used to estimate the relative risk (RR) of each AE.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 313 136 doses of PCV13 and 232 591 doses of PPSV23 were included. The adjusted RRs comparing the incidence of AEs following PCV13 vs PPSV23 were all &amp;lt;1, except for anaphylaxis, which was insignificant with an RR of 1.32 (95% confidence interval, 0.30\u20135.79). Only 1 patient who received PCV13 and 4 other vaccines concomitantly was confirmed by medical chart review as having experienced anaphylaxis after vaccination.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>These data do not support an increased rate of adverse events following PCV13 administration in elders compared with PPSV23 and should provide reassurance regarding continued use of PCV13.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofy100","type":"journal-article","created":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T05:14:54Z","timestamp":1525238094000},"source":"Crossref","is-referenced-by-count":19,"title":["Pneumococcal Conjugate Vaccine Safety in Elderly Adults"],"prefix":"10.1093","volume":"5","author":[{"given":"Hung Fu","family":"Tseng","sequence":"first","affiliation":[{"name":"Kaiser Permanente, Pasadena, Southern California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina S","family":"Sy","sequence":"additional","affiliation":[{"name":"Kaiser Permanente, Pasadena, Southern California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Qian","sequence":"additional","affiliation":[{"name":"Kaiser Permanente, Pasadena, Southern California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In-Lu A","family":"Liu","sequence":"additional","affiliation":[{"name":"Kaiser Permanente, Pasadena, Southern California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Mercado","sequence":"additional","affiliation":[{"name":"Kaiser Permanente, Pasadena, Southern California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Lewin","sequence":"additional","affiliation":[{"name":"Kaiser Permanente, Pasadena, Southern California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Y","family":"Tartof","sequence":"additional","affiliation":[{"name":"Kaiser Permanente, Pasadena, Southern California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Nelson","sequence":"additional","affiliation":[{"name":"Kaiser Permanente, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A","family":"Jackson","sequence":"additional","affiliation":[{"name":"Kaiser Permanente, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew F","family":"Daley","sequence":"additional","affiliation":[{"name":"Kaiser Permanente, Denver, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Weintraub","sequence":"additional","affiliation":[{"name":"Immunization Safety Office, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola P","family":"Klein","sequence":"additional","affiliation":[{"name":"Kaiser Permanente, Oakland, Northern California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Belongia","sequence":"additional","affiliation":[{"name":"Marshfield Clinic Research Institute, Marshfield, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth G","family":"Liles","sequence":"additional","affiliation":[{"name":"Kaiser Permanente, Northwest, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J","family":"Jacobsen","sequence":"additional","affiliation":[{"name":"Kaiser Permanente, Pasadena, Southern California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,5,2]]},"reference":[{"key":"2020081004282244200_CIT0001","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/1469-0691.12461","article-title":"Pneumococcal infection in adults: burden of disease","volume":"20","author":"Drijkoningen","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"2020081004282244200_CIT0002","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1086\/649839","article-title":"Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults","volume":"201","author":"Musher","year":"2010","journal-title":"J Infect Dis"},{"key":"2020081004282244200_CIT0003","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1086\/516521","article-title":"Persistence of antibodies to pneumococcal capsular polysaccharide vaccine in the elderly","volume":"176","author":"Sankilampi","year":"1997","journal-title":"J Infect Dis"},{"key":"2020081004282244200_CIT0004","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1378\/chest.10-0738","article-title":"Determining the optimal pneumococcal vaccination strategy for adults: is there a role for the pneumococcal conjugate vaccine","volume":"138","author":"Metersky","year":"2010","journal-title":"Chest"},{"key":"2020081004282244200_CIT0005","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/B978-1-4160-3611-1.50028-3","article-title":"Pneumococcal polysaccharide vaccines","volume-title":"Vaccines","author":"Jackson","year":"2008","edition":"5th ed"},{"key":"2020081004282244200_CIT0006","first-page":"1102","article-title":"Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23)","volume":"59","author":"Centers for Disease Control and Prevention (CDC)","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2020081004282244200_CIT0007","first-page":"816","article-title":"Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"61","author":"Centers for Disease Control and Prevention (CDC)","year":"2012","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2020081004282244200_CIT0008","doi-asserted-by":"crossref","first-page":"944","DOI":"10.15585\/mmwr.mm6434a4","article-title":"Intervals between PCV13 and PPSV23 vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"64","author":"Kobayashi","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2020081004282244200_CIT0009","first-page":"822","article-title":"Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged \u226565 years: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"63","author":"Tomczyk","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2020081004282244200_CIT0010","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa1408544","article-title":"Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults","volume":"372","author":"Bonten","year":"2015","journal-title":"N Engl J Med"},{"key":"2020081004282244200_CIT0011","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1542\/peds.2010-1722H","article-title":"The vaccine safety datalink: a model for monitoring immunization safety","volume":"127","author":"Baggs","year":"2011","journal-title":"Pediatrics"},{"key":"2020081004282244200_CIT0012","volume-title":"Vaccines and Related Biological Products Advisory Committee (VRBPAC) Adult Indication Briefing Document: Prevnar 13","author":"Food and Drug Administration","year":"2011"},{"key":"2020081004282244200_CIT0013","volume-title":"Prevnar 13 (Pneumococcal 13-valent conjugate vaccine [diphtheria CRM-197 protein]) [package insert]","year":"2015"},{"key":"2020081004282244200_CIT0014","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"key":"2020081004282244200_CIT0015","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1016\/j.vaccine.2013.05.010","article-title":"Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine","volume":"31","author":"Jackson","year":"2013","journal-title":"Vaccine"},{"key":"2020081004282244200_CIT0016","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1016\/j.vaccine.2013.04.085","article-title":"Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults","volume":"31","author":"Jackson","year":"2013","journal-title":"Vaccine"},{"key":"2020081004282244200_CIT0017","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1016\/j.vaccine.2014.02.002","article-title":"Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-na\u00efve adults 60-64 years of age","volume":"32","author":"Greenberg","year":"2014","journal-title":"Vaccine"},{"key":"2020081004282244200_CIT0018","doi-asserted-by":"crossref","first-page":"5195","DOI":"10.1016\/j.vaccine.2011.05.031","article-title":"A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged \u226565 years","volume":"29","author":"Schwarz","year":"2011","journal-title":"Vaccine"},{"key":"2020081004282244200_CIT0019","doi-asserted-by":"crossref","first-page":"123","DOI":"10.4236\/wjv.2013.34017","article-title":"Safety of a 13-valent pneumococcal conjugate vaccine in elderly adults previously immunized with a 23-valent pneumococcal polysaccharide vaccine: an open-label trial","volume":"3","author":"Schwarz","year":"2013","journal-title":"World J Vaccines"},{"key":"2020081004282244200_CIT0020","doi-asserted-by":"crossref","first-page":"6330","DOI":"10.1016\/j.vaccine.2016.10.052","article-title":"Post-licensure surveillance of 13-valent pneumococcal conjugate vaccine (PCV13) in adults aged 19 years old in the United States, Vaccine Adverse Event Reporting System (VAERS), June 1, 2012\u2013December 31, 2015","volume":"34","author":"Haber","year":"2016","journal-title":"Vaccine"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/5\/6\/ofy100\/33576459\/ofy100.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/5\/6\/ofy100\/33576459\/ofy100.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T08:30:27Z","timestamp":1597048227000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofy100\/4990792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,2]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofy100","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,6]]},"published":{"date-parts":[[2018,5,2]]},"article-number":"ofy100"}}